Acţiunile Novo Nordisk s-au prăbuşit vineri, după eşecul unui studiu clinic pentru un tratament cardiac

Novo Nordisk's shares fell significantly after its cardiovascular drug ziltivekimab failed to meet primary study goals. The treatment did not statistically reduce major cardiovascular events compared to placebo, despite some positive biological effects. The study involved over 6,300 patients with atherosclerotic cardiovascular disease and chronic kidney disease. Following the announcement, shares dropped by up to 10%, raising concerns about the company's credibility in drug development. However, Novo Nordisk has seen success with its weight loss drug Wegovy. Analysts believe the market reaction is exaggerated but warn that the failure limits growth opportunities outside obesity medications.